SCHEMBL6743969

SCHEMBL6743969

NC(c1ccccc1)C(N)c1ccccc1.[Ru]

nearest known ligand 0.93

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 2/20 0.93
F2 P00734 1/20 0.61
HTR2A P28223 1/20 0.48
TAAR1 Q96RJ0 1/20 0.48
ADRA2A P08913 1/20 0.46
ADRA2C P18825 1/20 0.46
LMNA P02545 1/20 0.46
HIF1A Q16665 1/20 0.46
KDM4E B2RXH2 1/20 0.46
TSHR P16473 1/20 0.45
ALDH1A1 P00352 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL644767 0.97 DPP4 (1.00) DPP4F2HTR2ATAAR1ADRA2A
SCHEMBL851654 0.97 DPP4 (1.00) DPP4F2HTR2ATAAR1ADRA2A
SCHEMBL2067094 0.97 DPP4 (1.00) DPP4F2HTR2ATAAR1ADRA2A
SCHEMBL150159 0.97 DPP4 (1.00) DPP4F2HTR2ATAAR1ADRA2A
SCHEMBL239938 0.97 DPP4 (1.00) DPP4F2HTR2ATAAR1ADRA2A
SCHEMBL1878642 0.97 DPP4 (1.00) DPP4F2HTR2ATAAR1ADRA2A
Ammonia Solution, Strong SCHEMBL4410348 0.93 DPP4 (0.93) DPP4F2HTR2ATAAR1ADRA2A
Hydrochloric Acid SCHEMBL9670481 0.93 DPP4 (0.93) DPP4F2HTR2ATAAR1ADRA2A
SCHEMBL31157895 0.93 DPP4 (0.93) DPP4F2HTR2ATAAR1ADRA2A
SCHEMBL10350027 0.93 DPP4 (0.93) DPP4F2HTR2ATAAR1ADRA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4460502-A1 DEUTERIUM-ENRICHED PIPERIDINYL-METHYL-PURINE AMINES AND RELATED COMPOUNDS AND THEIR USE IN TREATING DISEASES AND CONDITIONS K36 Therapeutics, Inc. (US) 2024-11-13 EP disclosed
WO-2023133201-A1 DEUTERIUM-ENRICHED PIPERIDINYL-METHYL-PURINE AMINES AND RELATED COMPOUNDS AND THEIR USE IN TREATING DISEASES AND CONDITIONS K36 THERAPEUTICS, INC. (US) 2023-07-13 WO disclosed
US-6696573-B1 SYNTHESIS OF SUCH AS 2-(N-(2-(9H-CARBAZOL-2-YLOXY)ETHYL))-AMINO-1-((3 -METHYLSULFONYLAMINO)PHENYL)ETHANOL WITH ENHANCED OPTICAL PURITY ASAHI KASEI KABUSHIKI KAISHA (JP) 2004-02-24 US disclosed
US-20030225289-A1 Process for the preparation of tricyclic amino alcohol derivatives ASAHI KASEI KABUSHIKI KAISHA (JP) 2003-12-04 US disclosed
EP-1209150-A1 PROCESSES FOR THE PREPARATION OF TRICYCLIC AMINO ALCOHOL DERIVATIVES Asahi Kasei Kabushiki Kaisha (JP) 2002-05-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225289-A1 Process for the preparation of tricyclic amino alcohol derivatives ADH1A, ADH1C, OXER1 DPP4 686/4885F2 511/4885HTR2A 1596/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.